{
    "nctId": "NCT05341141",
    "briefTitle": "Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy",
    "officialTitle": "Effectiveness of Cryotherapy Combined With Compression Therapy in Preventing Albumin-paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 102,
    "primaryOutcomeMeasure": "Incidence of grade 3 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged from 20 to 70 years old;\n2. Histologically confirmed as invasive breast cancer;\n3. HER-2 negative (defined by IHC 0 or 1+ ,or FISH negative);\n4. Participants who meet any of the following conditions: 1) T \\> 2 cm, ER\\<1% and PR\\<1%; 2) T \\> 2 cm, ER\u22651% and biopsy pathology (FNAB or CNB) diagnosed regional lymph node metastasis;\n5. Without any previous treatment;\n6. ddEC-ddT neoadjuvant chemotherapy is planned;\n7. Participants must have at least one measurable disease according to RECIST 1.1;\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n9. LVEF \u2265 50%;\n10. The ECG results are judged to be almost normal or normal, or the investigator judges that the abnormalities are not clinically significant;\n11. Bone marrow function: absolute neutrophil counts (ANC) \u2265 1.5x10\\^9/L, platelets \u2265 100x10\\^9/L, hemoglobin \u2265 90g/L;\n12. Liver and kidney function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are both \u22642.5 ULN; serum total bilirubin and serum creatinine are both \u2264 1.5 ULN;\n13. Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form.\n\nExclusion Criteria:\n\n1. Breast cancer with distant metastasis;\n2. A history of other malignancies;\n3. In the past or present, participants with sensory or motor neurological diseases;\n4. Participants who are known to be allergic to the active or other components of the study treatment;\n5. Cerebral thrombosis is present;\n6. In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate \\> 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 \\[Mobitz 2\\] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) ncontrolled hypertension (eg systolic blood pressure \\> 180mm Hg or diastolic blood pressure \\> 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure;\n7. Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active pepticulcer, unstable diabetes;\n8. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation;\n9. Participants who were judged by the investigator to be unsuitable for this study.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}